ChemoCentryx Company Profile (NASDAQ:CCXI)

About ChemoCentryx

ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company's pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases.

Industry, Sector and Symbol:

• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Exchange: NASDAQ
• Symbol: CCXI
• CUSIP: 16383L10

Key Metrics:

• Previous Close: $5.20
• 50 Day Moving Average: $4.65
• 200 Day Moving Average: $4.01
• 52-Week Range: $47,762,000.00 - $1.92
• Trailing P/E Ratio: N/A
• Foreward P/E Ratio: -4.92
• P/E Growth: 0.00
• Market Cap: $248.84M
• Outstanding Shares: 47,762,000
• Beta: 1.46

Profitability:

• Return on Equity: -70.89%
• Return on Assets: -51.68%

Debt:

• Current Ratio: 5.54%
• Quick Ratio: 5.54%

Additional Links:

• Visit ChemoCentryx's Official Website
• View CCXI on Google Finance
• View CCXI on Yahoo Finance
• View CCXI's Company Profile on Reuters
• Search for ChemoCentryx Inc. on Google

Companies Related to ChemoCentryx:

• Flexion Therapeutics (NASDAQ:FLXN)
• Ascendis Pharma AS (NASDAQ:ASND)
• Capital Senior Living Corp. (NYSE:CSU)
• CoLucid Pharmaceuticals (NASDAQ:CLCD)
• La Jolla Pharmaceutical (NASDAQ:LJPC)
• Lion Biotechnologies (NASDAQ:LBIO)
• OraSure Technologies (NASDAQ:OSUR)
• Accuray (NASDAQ:ARAY)
• Omeros Corporation (NASDAQ:OMER)
• MyoKardia (NASDAQ:MYOK)

Earnings

Earnings History for ChemoCentryx (NASDAQ:CCXI)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call	Details
11/7/2016
5/10/2016	Q1	($0.27)	($0.34)			View	Listen
3/14/2016	Q4	($0.28)	($0.26)			View	N/A
11/9/2015	Q315	($0.29)	($0.26)			View	Listen
8/6/2015	Q215	($0.29)	($0.28)			View	N/A
5/6/2015	Q115	($0.28)	($0.28)			View	Listen
3/12/2015	Q414	($0.28)	($0.28)			View	Listen
11/5/2014		($0.28)	($0.25)			View	N/A
5/8/2014	Q114	($0.24)	($0.27)	$0.38 million		View	N/A
3/13/2014		($0.25)	($0.22)			View	N/A
8/12/2013	Q2 2013	($0.28)	($0.23)	$1.48 million	$1.90 million	View	N/A
5/13/2013	Q1 2013	($0.27)	($0.28)	$2.04 million	$1.90 million	View	N/A
11/13/2012	Q312		($0.28)	$1.44 million	$1.13 million	View	N/A

(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ChemoCentryx (NASDAQ:CCXI)

Dividends

Dividend History for ChemoCentryx (NASDAQ:CCXI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ChemoCentryx (NASDAQ:CCXI)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Details
9/1/2016	Roger C Lucas	Director	Sell	4,000	$5.07	$20,280.00
5/23/2016	James L Tyree	Director	Sell	5,544	$4.39	$24,338.16
5/17/2016	Thomas A Edwards	Director	Buy	50,000	$4.05	$202,500.00
5/16/2016	Thomas A Edwards	Director	Buy	25,000	$4.05	$101,250.00
5/13/2016	Geoffrey M Parker	Director	Buy	40,000	$4.03	$161,200.00
1/22/2016	Susan M. Kanaya	CFO	Sell	25,764	$4.04	$104,086.56
1/20/2016	Susan M. Kanaya	CFO	Sell	14,971	$4.10	$61,381.10
1/19/2016	Susan M. Kanaya	CFO	Sell	6,134	$4.05	$24,842.70
1/15/2016	Susan M. Kanaya	CFO	Sell	300	$4.00	$1,200.00
1/11/2016	Geoffrey M Parker	Director	Buy	20,000	$4.63	$92,600.00
1/8/2016	Susan M. Kanaya	CFO	Sell	10,224	$5.12	$52,346.88
1/6/2016	Susan M. Kanaya	CFO	Sell	47,607	$6.98	$332,296.86
1/5/2016	Susan M. Kanaya	CFO	Sell	34,341	$6.90	$236,952.90
1/4/2016	Susan M. Kanaya	CFO	Sell	10,490	$7.38	$77,416.20
12/11/2015	Geoffrey M Parker	Director	Buy	20,000	$7.25	$145,000.00
11/4/2015	Value Fund L P Biotechnology	Insider	Sell	360,000	$7.00	$2,520,000.00
11/2/2015	Value Fund L P Biotechnology	Insider	Sell	50,000	$6.97	$348,500.00
6/10/2015	Bvf Partners L P/Il	Major Shareholder	Sell	955,700	$9.00	$8,601,300.00
5/22/2015	Ira Klein	Director	Sell	10,811	$7.44	$80,433.84
4/1/2015	Thomas J Schall	CEO	Sell	24,267	$7.50	$182,002.50
3/31/2015	Thomas J Schall	CEO	Sell	16,540	$7.55	$124,877.00
3/30/2015	Thomas J Schall	CEO	Sell	1,200	$7.51	$9,012.00
3/24/2015	Thomas J Schall	CEO	Sell	50,371	$7.84	$394,908.64
3/19/2015	Thomas J Schall	CEO	Sell	18,146	$8.34	$151,337.64
3/17/2015	Thomas J Schall	CEO	Sell	31,316	$8.55	$267,751.80
3/9/2015	Markus J Cappel	Treasurer	Sell	34,125	$7.81	$266,516.25
3/4/2015	Markus J Cappel	Treasurer	Sell	40,875	$7.98	$326,182.50
3/3/2015	Markus J Cappel	Treasurer	Sell	5,943	$7.81	$46,414.83
3/2/2015	Markus J Cappel	Treasurer	Sell	14,390	$8.13	$116,990.70
11/18/2014	Anne-Marie Duliege	EVP	Sell	4,970	$4.71	$23,408.70
5/1/2014	Thomas J Schall	CEO	Sell	27,726	$5.59	$154,988.34
4/29/2014	Thomas J Schall	CEO	Sell	32,274	$5.38	$173,634.12
4/22/2014	Markus J Cappel	Treasurer	Sell	20,962	$8.17	$171,259.54
3/17/2014	Thomas J Schall	CEO	Sell	20,000	$7.25	$145,000.00
12/6/2013	Geoffrey M Parker	Director	Buy	20,000	$5.15	$103,000.00
12/5/2013	Bvf Partners L P/Il	Major Shareholder	Buy	189,800	$5.01	$950,898.00
11/6/2013	Bvf Partners L P/Il	Major Shareholder	Buy	136,066	$4.92	$669,444.72
11/1/2013	Bvf Partners L P/Il	Major Shareholder	Buy	336,225	$4.99	$1,677,762.75
10/9/2013	Bvf Partners L P/Il	Major Shareholder	Buy	1,289,354	$5.34	$6,885,150.36
10/3/2013	Bvf Partners L P/Il	Major Shareholder	Buy	109,425	$5.49	$600,743.25
9/13/2013	Bvf Partners L P/Il	Major Shareholder	Buy	325,635	$5.95	$1,937,528.25
9/13/2013	Joseph M Feczko	Director	Buy	10,000	$6.03	$60,300.00
8/13/2013	Markus J Cappel	Treasurer	Sell	5,459	$12.90	$70,421.10
8/7/2013	Petrus Bekker	SVP	Sell	5,000	$13.26	$66,300.00
8/5/2013	Roger C Lucas	Director	Sell	5,000	$13.42	$67,100.00
8/1/2013	Markus J Cappel	Treasurer	Sell	6,250	$13.82	$86,375.00
7/17/2013	Markus J Cappel	Treasurer	Sell	5,459	$14.52	$79,264.68
7/17/2013	Petrus Bekker	SVP	Sell	10,000	$14.54	$145,400.00
7/16/2013	Thomas J Schall	CEO	Sell	22,089	$14.39	$317,860.71
7/3/2013	Roger C Lucas	Director	Sell	5,000	$13.43	$67,150.00
7/2/2013	Markus J Cappel	Treasurer	Sell	6,250	$13.88	$86,750.00
6/28/2013	Susan M Kanaya	CFO	Sell	36,942	$14.31	$528,640.02
6/27/2013	Petrus Bekker	SVP	Sell	5,000	$14.00	$70,000.00
6/21/2013	Markus J Cappel	Treasurer	Sell	6,250	$13.00	$81,250.00
6/18/2013	Markus J Cappel	Treasurer	Sell	1,783	$12.47	$22,234.01
6/17/2013	Petrus Bekker	SVP	Sell	5,000	$12.00	$60,000.00
6/3/2013	Roger C Lucas	Director	Sell	5,000	$13.32	$66,600.00
5/30/2013	Susan M Kanaya	CFO	Sell	12,770	$14.28	$182,355.60
5/28/2013	Markus J Cappel	Treasurer	Sell	3,676	$14.10	$51,831.60
5/24/2013	Petrus Bekker	SVP	Sell	4,800	$14.00	$67,200.00
5/17/2013	Petrus Bekker	SVP	Sell	15,000	$13.97	$209,550.00
5/15/2013	Markus J Cappel	Treasurer	Sell	15,668	$14.08	$220,605.44
5/15/2013	Roger C Lucas	Director	Sell	5,000	$14.11	$70,550.00
5/15/2013	Thomas J Schall	CEO	Sell	7,600	$14.04	$106,704.00
4/11/2013	Markus J Cappel	Treasurer	Sell	1,500	$14.10	$21,150.00
4/11/2013	Petrus Bekker	SVP	Sell	3,979	$14.03	$55,825.37
4/11/2013	Thomas J Schall	CEO	Sell	2,529	$14.02	$35,456.58
3/6/2013	Petrus Bekker	SVP	Sell	11,502	$13.98	$160,797.96
3/6/2013	Thomas J Schall	CEO	Sell	5,541	$14.01	$77,629.41
3/4/2013	Roger C Lucas	Director	Sell	5,000	$13.87	$69,350.00
2/26/2013	Juan C Jaen	SVP	Sell	22,500	$12.23	$275,175.00
2/22/2013	Thomas J Schall	CEO	Sell	7,500	$12.06	$90,450.00
2/6/2013	Roger C Lucas	Director	Sell	3,857	$11.52	$44,432.64
2/4/2013	Juan C Jaen	SVP	Sell	3,875	$11.69	$45,298.75
1/17/2013	Markus J Cappel	Treasurer	Sell	2,700	$11.16	$30,132.00
11/6/2012	Bvf Partners L P/Il	Major Shareholder	Buy	40,000	$12.00	$480,000.00
10/4/2012	Roger C Lucas	Director	Sell	1,893	$11.47	$21,712.71
10/1/2012	Susan M Kanaya	CFO	Sell	3,971	$11.89	$47,215.19
10/1/2012	Thomas J Schall	CEO	Sell	15,000	$11.53	$172,950.00

(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ChemoCentryx (NASDAQ:CCXI)

Date	Headline
	On the Move Insider Trading: ChemoCentryx Inc (NASDAQ:CCXI ... - Post Registrar (NASDAQ:CCXI) postregistrar.com - September 7 at 9:25 AM
	ChemoCentryx Inc (NASDAQ:CCXI): Here’s Our Take (NASDAQ:CCXI) streetregister.com - September 6 at 9:03 PM
	Average Price Target for ChemoCentryx, Inc. (NASDAQ:CCXI) is $11 - Newburg Press (NASDAQ:CCXI) newburghpress.com - September 6 at 4:01 PM
	Biotech news that matter for investors: ChemoCentryx, Inc. (NASDAQ:CCXI), Dynavax Technologies Corporation ... - The Voice Registrar (NASDAQ:CCXI) voiceregistrar.com - September 6 at 4:01 PM
	ChemoCentryx Inc (NASDAQ:CCXI): Here's Our Take - Street Register (NASDAQ:CCXI) streetregister.com - September 6 at 4:01 PM
	Active Biotech Stock News: ChemoCentryx, Inc. (CCXI), Threshold Pharmaceuticals Inc. (THLD) - The Independent Republic (NASDAQ:CCXI) theindependentrepublic.com - September 6 at 8:57 AM
	NASDAQ Composite Index Rises Again after Markets Digest Payrolls Data (NASDAQ:CCXI) www.economiccalendar.com - September 3 at 8:47 AM
	Mid-Day Market Update: Crude Oil Up 3%; VeriFone Shares Decline On Lowered Forecast (NASDAQ:CCXI) www.benzinga.com - September 2 at 3:56 PM
	Mid-Afternoon Market Update: Accuride Jumps Following Acquisition Announcement; Lululemon Shares Slide (NASDAQ:CCXI) www.stockhouse.com - September 2 at 3:56 PM
	ChemoCentryx (CCXI) Announces Interim ORR Data from CCX872 Phase 1b in Adv. Pancreatic Cancer (NASDAQ:CCXI) www.streetinsider.com - September 2 at 3:56 PM
	Why ChemoCentryx Inc (NASDAQ:CCXI) Tanked Today (NASDAQ:CCXI) marketexclusive.com - September 2 at 3:56 PM
	ChemoCentryx's CCX872 appears safe in early-stage pancreatic cancer study; shares off 10% premarket (NASDAQ:CCXI) seekingalpha.com - September 2 at 9:27 AM
	ChemoCentryx (CCXI) Announces Interim ORR Data from CCX872 Phase 1b in Adv. Pancreatic Cancer - StreetInsider.com (NASDAQ:CCXI) www.streetinsider.com - September 2 at 8:56 AM
	ChemoCentryx Reports Initial Results from Ongoing Phase Ib Clinical Trial of CCX872 in Patients with Advanced Pancreatic Cancer (NASDAQ:CCXI) finance.yahoo.com - September 2 at 8:56 AM
	4:09 pm ChemoCentryx announces initial 12 week overall response rate results from an ongoing open label, single arm Phase Ib clinical trial with CCX872 in patients with advanced pancreatic cancer (NASDAQ:CCXI) finance.yahoo.com - September 2 at 8:56 AM
	Stock on the Rise in Session: ChemoCentryx, Inc. (NASDAQ:CCXI) - Post News (NASDAQ:CCXI) www.kentuckypostnews.com - August 31 at 4:03 PM
	ChemoCentryx to Present at the Baird 2016 Global Healthcare Conference (NASDAQ:CCXI) finance.yahoo.com - August 25 at 8:59 AM
	CHEMOCENTRYX, INC. Financials (NASDAQ:CCXI) finance.yahoo.com - August 17 at 4:14 PM
	ChemoCentryx, Inc. (CCXI) (NASDAQ:CCXI) finance.yahoo.com - August 15 at 9:45 PM
	CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:CCXI) biz.yahoo.com - August 9 at 4:24 PM
	Edited Transcript of CCXI earnings conference call or presentation 8-Aug-16 9:00pm GMT (NASDAQ:CCXI) finance.yahoo.com - August 9 at 4:24 PM
	ChemoCentryx reports 2Q loss (NASDAQ:CCXI) sg.finance.yahoo.com - August 8 at 9:34 PM
	ChemoCentryx Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:CCXI) finance.yahoo.com - August 8 at 4:13 PM
	Q2 2016 ChemoCentryx Inc Earnings Release - After Market Close (NASDAQ:CCXI) biz.yahoo.com - August 8 at 8:57 AM
	ChemoCentryx, Inc. (NASDAQ:CCXI) Updated Price Targets - FTSE ... - FTSE News (NASDAQ:CCXI) www.ftsenews.co.uk - August 2 at 8:56 AM
	ChemoCentryx to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August 8, 201 (NASDAQ:CCXI) www.nasdaq.com - August 1 at 8:58 AM
	ChemoCentryx to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August 8, 2016 (NASDAQ:CCXI) finance.yahoo.com - August 1 at 8:30 AM
	Insiders Increasing Positions in: ChemoCentryx, Inc. (NASDAQ:CCXI) - Press Telegraph (NASDAQ:CCXI) presstelegraph.com - July 21 at 8:01 AM
	ChemoCentryx Inc. (CCXI) Drops 5.04% on July 19 - Equities.com (NASDAQ:CCXI) www.equities.com - July 20 at 11:25 PM
	Chemocentryx Incorporated (NASDAQ:CCXI) Short Interest Decreased By 23.13% - Consumer Eagle (NASDAQ:CCXI) www.consumereagle.com - July 20 at 12:10 PM
	Heightened Volatility Spotted on Shares of: ChemoCentryx, Inc. (NASDAQ:CCXI) - Engelwood Daily (NASDAQ:CCXI) www.engelwooddaily.com - July 20 at 12:10 PM
	Chemocentryx Incorporated (NASDAQ:CCXI) Short Interest Decreased By 1.58% - Consumer Eagle (NASDAQ:CCXI) www.consumereagle.com - July 18 at 4:22 PM
	Shares Experiencing a Downtrend: ChemoCentryx, Inc. (NASDAQ:CCXI) - TGP (NASDAQ:CCXI) telanaganapress.com - July 16 at 11:10 AM
	Chemocentryx Incorporated (NASDAQ:CCXI) Sellers Covered 1.58% of Their Shorts - Consumer Eagle (NASDAQ:CCXI) www.consumereagle.com - July 14 at 10:27 AM
	Institutional Investors Love Chemocentryx Inc (NASDAQ:CCXI) - Consumer Eagle (NASDAQ:CCXI) www.consumereagle.com - July 12 at 8:20 AM
	Stock on the Rise for the Quarter: ChemoCentryx, Inc. (NASDAQ:CCXI) - Engelwood Daily (NASDAQ:CCXI) www.engelwooddaily.com - July 11 at 8:57 AM
	ChemoCentryx, Inc. (NASDAQ:CCXI) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:CCXI) www.fiscalstandard.com - July 11 at 8:57 AM
	New Broker Ratings For ChemoCentryx, Inc. (NASDAQ:CCXI) - FTSE News (NASDAQ:CCXI) www.ftsenews.co.uk - July 7 at 11:58 AM
	Insiders are Gradually Selling ChemoCentryx, Inc. (NASDAQ:CCXI) - Telanagana Press (NASDAQ:CCXI) telanaganapress.com - July 7 at 11:58 AM
	ChemoCentryx Inc. (CCXI) Jumps 5.57% on July 04 - Equities.com (NASDAQ:CCXI) www.equities.com - July 6 at 4:13 PM
	Chemocentryx Incorporated (NASDAQ:CCXI) Shorts Decreased by 1.58% After Short Covering - Engelwood Daily (NASDAQ:CCXI) www.engelwooddaily.com - July 5 at 8:52 AM
	Tracking Stock Volatility for: ChemoCentryx, Inc. (NASDAQ:CCXI) - Engelwood Daily (NASDAQ:CCXI) www.engelwooddaily.com - July 2 at 4:10 PM
	ChemoCentryx Inc. (CCXI) Jumps 5.57% on July 01 - Equities.com (NASDAQ:CCXI) www.equities.com - July 2 at 4:10 PM
	ChemoCentryx : to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference (NASDAQ:CCXI) www.4-traders.com - June 30 at 11:57 AM
	Stock Tracking Lower in Session: ChemoCentryx, Inc. (NASDAQ:CCXI) - Telanagana Press (NASDAQ:CCXI) telanaganapress.com - June 29 at 9:12 PM
	Watching Stock Volatility for: ChemoCentryx, Inc. (NASDAQ:CCXI) - Engelwood Daily (NASDAQ:CCXI) www.engelwooddaily.com - June 29 at 9:12 PM
	ChemoCentryx, Inc. (NASDAQ:CCXI) Current Analyst Ratings - Fiscal Standard (NASDAQ:CCXI) www.fiscalstandard.com - June 29 at 9:12 PM
	ChemoCentryx to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference (NASDAQ:CCXI) finance.yahoo.com - June 29 at 8:30 AM
	Next Weeks Broker Price Targets For ChemoCentryx, Inc. (NASDAQ:CCXI) - Fiscal Standard (NASDAQ:CCXI) www.fiscalstandard.com - June 28 at 8:59 AM
	Stock to Keep Your Eyes on: ChemoCentryx, Inc. (CCXI) - iStreetWire (NASDAQ:CCXI) istreetwire.com - June 24 at 6:25 AM

Social

ChemoCentryx (NASDAQ:CCXI) Chart for Monday, September, 26, 2016